Evaluation Of Novel Boron Compound For Boron Neutron Capture Therapy Using Rat Brain Tumor Model
Morressier, 2017
Online
unknown
IntroductionBoron neutron capture therapy (BNCT) is form of tumor-cell selective particle irradiation using low energy neutron irradiation of non-radioactive boron-10 (10B) to produce high energy alpha particles (10B [n, alpha] 7Li). To develop practical materials utilizing 10B carriers, we designed and synthesized novel boron drug (AAL) which is the compound containing many boron-10 atoms like BSH, utilizing the amino acid demand enhanced by tumor like BPA, and combines the characteristics of both.Materials and MethodsWe evaluated the boron concentration of F98 glioma cells for 10B compounds, BPA, and AAL in vitro, and the biodistribution of these following BPA administrated intravenously (i.v.) or AAL administrated by convection-enhanced delivery (CED) in F98 glioma bearing rats. For in vivo, F98 glioma bearing rats were divided to six groups.ResultsIn vitro, AAL attained higher cellular uptake F98 glioma cells compared with BSH, but less than BPA. In vivo biodistribution study, the AAL(CED) 6h after termination group attained highest boron concentrations of tumor (59.9 u00b1 18.2 u03bcg/g). The corresponding ipsilateral normal brain concentrations were low (2.9 u00b1 0.5 u03bcg/g). Median survival times (MST) of untreated and irradiated controls were 26.5 (25-28) and 28 (26-30) days, respectively, while rats that received AAL(CED), followed by BNCT, had a MST of 31 (29-35) days, which were shorter than those obtained following i.v. administration of BPA (34 (33-36) days). And the combination group had a MST of 38 (36-40) days. ConclusionThis study suggested the possibility that AAL became the drug to add curative effect for BNCT.
Titel: |
Evaluation Of Novel Boron Compound For Boron Neutron Capture Therapy Using Rat Brain Tumor Model
|
---|---|
Autor/in / Beteiligte Person: | Kanemitsu, Takuya |
Link: | |
Veröffentlichung: | Morressier, 2017 |
Medientyp: | unknown |
Sonstiges: |
|